According to Wu, Nasdaq-listed company Liminatus Pharma (LIMN) announced plans to establish a subsidiary called "American BNB Strategy" and aims to raise up to $500 million, focusing on long-term investments in BNB assets. The plan is still subject to board approval and has not yet formed an entity or completed financing arrangements. The company stated that this initiative aims to expand long-term growth opportunities without impacting its core business of cancer immunotherapy.

BNB-1.45%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)